000 01439 a2200409 4500
005 20250517154824.0
008 ####s 0 0 eng d
022 _a1462-0332
024 7 _a10.1093/rheumatology/kex218
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aMcCarthy, Eoghan M
245 0 0 _aThe potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales.
_h[electronic resource]
260 _bRheumatology (Oxford, England)
_c06 2017
300 _a1049 p.
_bdigital
500 _aPublication Type: Journal Article; Published Erratum
700 1 _aSutton, Emily
700 1 _aNesbit, Stephanie
700 1 _aParker, Ben
700 1 _aJayne, David
700 1 _aGriffiths, Bridget
700 1 _aIsenberg, David A
700 1 _aRahman, Anisur
700 1 _aGordon, Caroline
700 1 _aD'Cruz, David P
700 1 _aRhodes, Benjamin
700 1 _aLanyon, Peter
700 1 _aVital, Edward M
700 1 _aYee, Chee-Seng
700 1 _aEdwards, Christopher J
700 1 _aTeh, Lee-Suan
700 1 _aAkil, Mohammed
700 1 _aMcHugh, Neil J
700 1 _aZoma, Asad
700 1 _aBruce, Ian N
773 0 _tRheumatology (Oxford, England)
_gvol. 56
_gno. 6
_gp. 1049
856 4 0 _uhttps://doi.org/10.1093/rheumatology/kex218
_zAvailable from publisher's website
999 _c27214541
_d27214541